^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1d
    Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    1d
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    3d
    Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors (clinicaltrials.gov)
    P1, N=30, Suspended, Wondercel Biotech (ShenZhen) | Recruiting --> Suspended
    Trial suspension
    |
    CD19 positive
    |
    fludarabine IV
    3d
    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, University of Alberta | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    CD19 positive
    |
    clonoSEQ
    |
    Iclusig (ponatinib)
    10d
    Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases (clinicaltrials.gov)
    P=N/A, N=72, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    CRP (C-reactive protein)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    17d
    Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Affiliated Hospital to Academy of Military Medical Sciences
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide
    17d
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Beijing Tongren Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Apr 2026
    Enrollment closed • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    26d
    KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, TCRx Therapeutics Co.Ltd | N=30 --> 18 | Initiation date: May 2025 --> Sep 2025 | Trial primary completion date: Jun 2028 --> Dec 2028
    Enrollment change • Trial initiation date • Trial primary completion date
    |
    CD19 positive
    26d
    SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Beijing Biotech
    New P1/2 trial • IO biomarker
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    26d
    CD19-Negative Acute Lymphoblastic Leukemia (ALL): A Case Report and Review of Literature on a Rare Phenomenon De Novo and a Future Induced Struggle in Relapse. (PubMed, Int J Mol Sci)
    Many are associated with hypercalcemia and osteolytic lesions. However, here we highlight the clinical impact of the more common secondary form of CD19-negative B-ALL as a relapse of CD19-positive ALL, right after the administration of targeted immunotherapy.
    Review • Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • MME (Membrane Metalloendopeptidase)
    |
    CD19 positive
    1m
    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=26, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2027 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • cyclophosphamide • Blincyto (blinatumomab) • vincristine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    1m
    CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Affiliated Hospital to Academy of Military Medical Sciences | Initiation date: Aug 2025 --> Apr 2026
    Trial initiation date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV